Relevant articles and documents
All total 20 Articles be found
A Preparation method of Taurine surfactant derived from natural oil
-
Paragraph 0098-0100; 0102, (2021/05/11)
The present invention relates to a process for preparing taurine based surfactants from natural oils. The present invention relates to a method for preparing a taurine surfactant, and more particularly, to a method for preparing a taurine surfactant by direct reaction of taurine with natural oil without further processing. In addition, the taurine-based surfactant produced by the method may be used as an efficient raw material, has excellent physical properties and detergency, and has excellent cleaning power when the detergent composition and detergent are prepared.
Preparation method of sodium taurate
-
Paragraph 0093-0095, (2020/05/30)
The invention provides a preparation method of sodium taurate. The preparation method comprises the following steps: dissolving sodium hydroxyethyl sulfonate and a raw material sodium taurate into a guanidyl-containing ionic liquid, performing a reaction to obtain an ionic liquid solution containing a mixed product of sodium ditaurate and sodium tritaurate, introducing liquid ammonia into the ionic liquid solution of the mixed product, performing a reaction to obtain an ionic liquid solution of the product sodium taurate, adding the ionic liquid solution of the product sodium taurate into an alcohol solvent for solvating out, and separating out the obtained precipitated solid to obtain the product sodium taurate. The sodium taurate preparation method is high in product yield, good in purity, high in raw material utilization rate, simple and convenient in process and mild in reaction condition, the production efficiency of sodium taurate can be greatly improved, and the production costis reduced, so that the sodium taurate preparation method has a very good industrial application prospect.
PEPTIDIC LINKERS AND CRYPTOPHYCIN CONJUGATES, USEFUL IN THERAPY, AND THEIR PREPARATION
-
Page/Page column 239; 240, (2018/12/02)
The present disclosure relates to compounds of formula (I): RCG1-L-P (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.